Barwell Plc
VC Fund
Barwell Plc is a VC fund focused on Software and Health Care. Barwell is a privately-funded venture capital company that is based in Glasgow, Scotland.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Barwell Plc invests in
Stages Barwell Plc invests in
Countries Barwell Plc invests in
Round sizes
Round size
- Series A
- $3M–$4.3M
- Series B
- $1.7M–$6.4M
Investment Focus
Industry
- Software 2 (22%)
- Health Care 2 (22%)
- Biotechnology 2 (22%)
- Medical Device 2 (22%)
- Information Technology 2 (22%)
Stage
- Series A 2 (22%)
- Series B 2 (22%)
- Angel 1 (11%)
- Funding Round 1 (11%)
- Venture - Series Unknown 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
MGB Biopharma
|
MGB Biopharma Limited is a biopharmaceutical company established to develop a completely new class of anti-infective medicines based upon compounds which are DNA Minor Groove Binders (MGB)The company has an exceptionally experienced team from both pharma and biotech sectors and is dedicating its focus initially to the development of smallmolecules with specific antibacterial efffects against resistant bacteriaBy selecting a new class of antibacterial, the company believes the novel mode of action should prove to be very potent against bacteria as these target organisms will lack any inherent resistance, unlike that typically facing new drugs which are the result of modifications from existing classes of drugs used to treat bacterial infection | Venture - Series Unknown / Aug 30, 2019 | |
|
MGB Biopharma
|
MGB Biopharma Limited is a biopharmaceutical company established to develop a completely new class of anti-infective medicines based upon compounds which are DNA Minor Groove Binders (MGB)The company has an exceptionally experienced team from both pharma and biotech sectors and is dedicating its focus initially to the development of smallmolecules with specific antibacterial efffects against resistant bacteriaBy selecting a new class of antibacterial, the company believes the novel mode of action should prove to be very potent against bacteria as these target organisms will lack any inherent resistance, unlike that typically facing new drugs which are the result of modifications from existing classes of drugs used to treat bacterial infection | $1.7M / Venture - Series Unknown / Sep 14, 2018 | |
|
MGB Biopharma
|
MGB Biopharma Limited is a biopharmaceutical company established to develop a completely new class of anti-infective medicines based upon compounds which are DNA Minor Groove Binders (MGB)The company has an exceptionally experienced team from both pharma and biotech sectors and is dedicating its focus initially to the development of smallmolecules with specific antibacterial efffects against resistant bacteriaBy selecting a new class of antibacterial, the company believes the novel mode of action should prove to be very potent against bacteria as these target organisms will lack any inherent resistance, unlike that typically facing new drugs which are the result of modifications from existing classes of drugs used to treat bacterial infection | $1.1M / Venture - Series Unknown / Apr 06, 2017 | |
Lamellar Biomedical
|
Lamellar Biomedical Ltd was established in June 2007 when the founding Directors of the Company, recognising the considerable therapeutic potential of Lamellasomes™, acquired the intellectual property rights to the technology. | $3M / Jul 24, 2015 | |
|
MGB Biopharma
|
MGB Biopharma Limited is a biopharmaceutical company established to develop a completely new class of anti-infective medicines based upon compounds which are DNA Minor Groove Binders (MGB)The company has an exceptionally experienced team from both pharma and biotech sectors and is dedicating its focus initially to the development of smallmolecules with specific antibacterial efffects against resistant bacteriaBy selecting a new class of antibacterial, the company believes the novel mode of action should prove to be very potent against bacteria as these target organisms will lack any inherent resistance, unlike that typically facing new drugs which are the result of modifications from existing classes of drugs used to treat bacterial infection | $6.4M / Series B / Sep 17, 2014 | |
Connect-In Ltd
|
Connect-In Ltd. stands for innovative Bluetooth IoT solutions, sustainable development, and state-of-the art design. Their sensors are built to be long lasting and power efficient (lasts 1-4 years on replaceable coin cell batteries) to make IoT understandable, accessible, and affordable, and to power the next generation of the Internet of Things. | Angel / Apr 30, 2014 | |
|
Lamellar Biomedical
|
Lamellar Biomedical Ltd was established in June 2007 when the founding Directors of the Company, recognising the considerable therapeutic potential of Lamellasomes™, acquired the intellectual property rights to the technology. | $4.3M / Series A / Jan 07, 2013 | |
|
MGB Biopharma
|
MGB Biopharma Limited is a biopharmaceutical company established to develop a completely new class of anti-infective medicines based upon compounds which are DNA Minor Groove Binders (MGB)The company has an exceptionally experienced team from both pharma and biotech sectors and is dedicating its focus initially to the development of smallmolecules with specific antibacterial efffects against resistant bacteriaBy selecting a new class of antibacterial, the company believes the novel mode of action should prove to be very potent against bacteria as these target organisms will lack any inherent resistance, unlike that typically facing new drugs which are the result of modifications from existing classes of drugs used to treat bacterial infection | $3M / Series A / Mar 31, 2010 | |
Factonomy
|
Founded in 2003 by Graeme Bryce and Dave Reynolds, Factonomy licenses its technology framework to companies to help them reduce the time and cost it takes to develop applications. Factonomy's agile software environment enables the rapid development of web-enabled business applications using declarative XML only. Unlike other developmentplatforms, the Factonomy Framework allows developers to work independently on functionality, content and style, providing a coherent end-to-end environment so they can deliver solutions which are flexible and cost effective. | $1.7M / Series B / May 30, 2008 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Barwell Plc invest in?
Barwell Plc invests primarily in Software, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Barwell Plc's check size?
Barwell Plc typically joins rounds of $3M–$4.3M at Series A and $1.7M–$6.4M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Barwell Plc participates in.
When did Barwell Plc last invest?
The most recent investment recorded for Barwell Plc closed in Aug 2019. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
